TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
TG Therapeutics Inc (TGTX) Financials: Revenue, Profit and Cash Flow
TG Therapeutics reported revenue of $616.29M for the fiscal year ended Dec 31, 2025, up 87.3% from the year before. That year, net income was $447.18M with a net margin of 72.6%, operating cash flow was -$24.77M and free cash flow was -$24.99M. The quarter ended Jun 30, 2026 had revenue of $240.34M and net income of $7.78M.
Revenue and Margins
The operating margin was 20.0% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $152.00K, a compound annual rate of 151.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $616.29M | +87.3% | 83.7% | 20.0% | 72.6% |
| Dec 2024 | $329.00M | +40.8% | 88.3% | 12.7% | 7.1% |
| Dec 2023 | $233.66M | +8290.0% | 94.0% | 8.8% | 5.4% |
| Dec 2022 | $2.79M | -58.4% | 100.0% | -7839.0% | -8036.3% |
| Dec 2021 | $6.69M | +4300.7% | 88.2% | -5154.3% | -5204.1% |
| Dec 2020 | $152.00K | 0.0% | 100.0% | -179996.1% | -183803.3% |
| Dec 2019 | $152.00K | 0.0% | 100.0% | -111220.4% | -113730.9% |
| Dec 2018 | $152.00K | 0.0% | 100.0% | -114736.8% | -114132.9% |
| Dec 2017 | $152.00K | 0.0% | 100.0% | -78100.0% | -77944.7% |
| Dec 2016 | $152.00K | N/A | 100.0% | -51953.3% | -51482.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1812.7% from the year before. In the quarter ended Jun 2026, net income fell 72.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M | $152.00K | $152.00K | $152.00K | $152.00K | $152.00K |
| Cost of revenue | $100.71M | $38.49M | $14.13M | $0 | $790.00K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $515.57M | $290.52M | $219.53M | $2.79M | $5.90M | $152.00K | $152.00K | $152.00K | $152.00K | $152.00K |
| Research and development | $160.22M | $94.29M | $76.19M | $125.35M | $222.58M | $165.90M | $154.18M | $159.39M | $102.53M | $69.23M |
| Operating income | $123.32M | $41.93M | $20.63M | -$218.32M | -$344.77M | -$273.59M | -$169.06M | -$174.40M | -$118.71M | -$78.97M |
| Net income | $447.18M | $23.38M | $12.67M | -$223.81M | -$348.10M | -$279.38M | -$172.87M | -$173.48M | -$118.48M | -$78.25M |
| EBITDA | $131.79M | $44.91M | $26.24M | -$211.59M | -$340.37M | -$271.78M | -$166.79M | -$172.50M | -$117.36M | -$78.05M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $240.34M | $204.92M | $192.57M | $161.71M | $141.15M | $120.86M | $108.19M | $83.88M | $73.47M | $63.47M | $43.97M | $165.81M |
| Gross profit | $199.14M | $171.41M | $154.43M | $133.62M | $122.21M | $105.31M | $92.78M | $74.54M | $65.16M | $58.03M | $34.20M | $162.31M |
| Operating income | $21.67M | $34.80M | $50.49M | $29.36M | $34.84M | $8.62M | $29.95M | $12.43M | $8.82M | -$9.27M | -$12.48M | $114.78M |
| Net income | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M | $5.06M | $23.33M | $3.88M | $6.88M | -$10.71M | -$14.42M | $113.93M |
Balance Sheet
As of Dec 2025, total debt of $246.69M exceeded cash and equivalents by $167.54M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.06B | $577.69M | $329.59M | $193.57M | $379.63M | $625.64M | $163.01M | $83.62M | $97.38M | $54.78M |
| Current assets | $630.76M | $566.36M | $317.94M | $168.27M | $330.96M | $611.74M | $149.15M | $79.03M | $93.32M | $50.86M |
| Cash and equivalents | $79.15M | $179.89M | $92.93M | $102.30M | $298.89M | $553.44M | $112.64M | $41.96M | $56.72M | $25.03M |
| Total liabilities | $415.23M | $355.33M | $169.09M | $134.99M | $142.48M | $106.29M | $124.40M | $59.58M | $30.39M | $18.91M |
| Short-term debt | $1.04M | $1.16M | $1.45M | $1.58M | $975.00K | $22.18M | $0 | $67.00K | $128.00K | $68.88K |
| Long-term debt | $245.65M | $244.43M | $100.12M | $71.14M | $66.79M | $7.72M | $28.97M | $0 | $0 | $0 |
| Shareholder equity | $648.02M | $222.36M | $160.50M | $58.59M | $237.15M | $519.35M | $38.62M | $24.04M | $66.99M | $35.87M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.64B | $1.53B | $1.06B | $1.03B | $702.61M | $656.69M | $577.69M | $586.01M | $401.21M | $373.32M | $329.59M | $331.07M |
| Total liabilities | $1.04B | $945.71M | $415.23M | $417.81M | $426.18M | $419.40M | $355.33M | $393.86M | $223.64M | $213.21M | $169.09M | $166.30M |
| Cash and equivalents | $482.57M | $442.21M | $79.15M | $74.08M | $129.13M | $132.14M | $179.89M | $195.82M | $82.91M | $75.48M | $92.93M | $150.90M |
| Shareholder equity | $604.08M | $583.13M | $648.02M | $607.22M | $276.43M | $237.29M | $222.36M | $192.16M | $177.57M | $160.11M | $160.50M | $164.77M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.77M | -$40.52M | -$31.41M | -$176.17M | -$295.63M | -$214.51M | -$132.81M | -$128.93M | -$93.76M | -$63.15M |
| Capital expenditures | $214.00K | $45.00K | $0 | $14.00K | $401.00K | $357.00K | $131.00K | $90.00K | $2.00K | $344.00K |
| Free cash flow | -$24.99M | -$40.56M | -$31.41M | -$176.18M | -$296.04M | -$214.86M | -$132.94M | -$129.01M | -$93.76M | -$63.50M |
| Share repurchases | $91.24M | $8.76M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $13.80M | -$1.04M | -$50.65M | -$20.01M | -$332.00K | -$24.51M | -$718.00K | $1.18M | -$8.21M | $26.55M |
| Financing cash flow | -$89.73M | $128.53M | $72.70M | -$391.00K | $41.42M | $679.83M | $204.21M | $113.64M | $133.66M | $5.02M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $39.26M | -$17.89M | $19.66M | -$23.15M | $7.44M | -$28.71M | -$25.64M | -$12.21M | $5.54M | -$8.21M | -$13.21M | $83.70M |
| Capital expenditures | $293.00K | $51.00K | $67.00K | $80.00K | $42.00K | $25.00K | $21.00K | $24.00K | $0 | $0 | $0 | $0 |
| Free cash flow | $38.97M | -$17.95M | $19.59M | -$23.23M | $7.39M | -$28.74M | -$25.66M | -$12.23M | $5.54M | -$8.21M | -$13.21M | $83.70M |
Frequently Asked Questions About TGTX
What is TG Therapeutics' annual revenue?
TG Therapeutics reported revenue of $616.29M for the fiscal year ended Dec 31, 2025.
How fast is TG Therapeutics' revenue growing?
Revenue was up 87.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 504.9%.
Is TG Therapeutics profitable?
Yes. TG Therapeutics reported net income of $447.18M for the fiscal year ended Dec 31, 2025, with a net margin of 72.6%.
How much free cash flow does TGTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.77M minus capital expenditures of $214.00K produced free cash flow of -$24.99M.
How much debt does TG Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $245.65M, short-term debt of $1.04M and cash and equivalents of $79.15M.
TGTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors